

Stability indicating method development and validation of Dexlansoprazole delayed-release capsules by using RP-HPLC Development and Validation of Dexlansoprazole delayed-release capsules

Santhosh Kumar Ettaboina

Analytical Research and Development, Aurex Laboratories Pvt. Ltd. Kukatpally, Hyderabad, Telangana, India, 500072.

Santhosh Kumar Ettaboina, Aurex Laboratories Pvt. Ltd. Kukatpally, Hyderabad, Telangana, India, 500072.

Date Of Submission: 20-03-2021

Date Of Acceptance: 05-04-2021

ABSTRACT: The present study describes the "Stability-indicating Method development and validation of Dexlansoprazole delayed release capsules using RP-HPLC" Isocratic separation was achieved by the use of X-Terra RP18column (250×4.6mm, 5μ), the mobile phase, consisting of a mixture of 10 mm dibasic potassium phosphate buffer, was prepared and the pH of the solution adjusted to 7.20 with dilute orthophosphoric acid: acetonitrile: TEA at a ratio of 70:30:1 v/v/v was delivered at a flow rate of 1.2 ml/min and a wavelength detector of 285nm. The retention time for Dexlansoprazole was 6.8 min. The linearity range of Dexlansoprazole was 50μg/mL-150 μg/mL-1 with a regression coefficient (r²) of 0.999, accurate (recovery 97.77-103.94%). Precision (RSD ≤ 1.0 percent), sensitive, specific, simple, fast and robust. Based on the validation parameters performed in accordance with the ICH guidelines, the proposed method was found to be specific, accurate and accurate for the analysis of Dexlansoprazole. The proposed method may be useful in quality control laboratories for the determination of Dexlansoprazole in pharmaceutical dosage form.

Keywords: Dexlansoprazole, Quality control, Reverse-phase high-performance liquid chromatography, Validation.

I. INTRODUCTION

Dexlansoprazole inhibits the H/K ATP ASE enzyme[1-3], which is involved in the secretion of hydrochloric acid, hydrolyzing ATP and exchanging H⁺ ions from the cytoplasm for K⁺ ions in the secretory canaliculus, which results in Hydrochloric acid secretion into the gastric lumen. Dexlansoprazole inhibits this effect of H/K ATPase by demonstrating a high degree of activation in the






acidic environment[4]. PPIs undergo protonation in the acidic pH setting after passing through the liver and reaching the gastric parietal cells stimulated by a meal, followed by conversion to Sulphenamide, the active form of the drug. Sulphenamide inhibits the activity of the proton pump[5] and hence the transport of hydrogen ions into the gastric lumen via covalent binding to the SH groups of the cysteine residues of H/K ATPase[6]. Dexlansoprazole MR delivery technology is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum (25 percent of total drug dose) and the second in the more distal small intestine (75 percent of total drug dose). Dexlansoprazole reduces both basal and stimulated gastric acid secretion[7]. Dexlansoprazole has a unique active formulation independent of time-of-day dosing or food[8]. Dexlansoprazole is the R-enantiomer of lansoprazole[9], Dexlansoprazole blocks in the final step of acid production[10].

Dexlansoprazole For the treatment of acid reflux disorders[11-12] (GERD), Peptic Ulcer disease[13-15], and H. Pylori eradication. Chemical name is (R)-(+)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfanyl)-1H-benzimidazole. Dexlansoprazole is freely soluble in methanol, ethanol & ethyl acetate[16-17], Soluble in Acetonitrile: slightly soluble in ether; very slightly soluble in water; practically insoluble in hexane[18]. Dexlansoprazole is class of Benzimidazoles, Ethers[19]. Its Molecular formula is C₁₆H₁₄F₃N₃O₂S & Molecular weight is 369.36 gm/mole. The aim of the current study was to create a highly effective sensitive method for Dexlansoprazole bulk estimation and formulations and validation in compliance with ICH guidelines[20]. Dexlansoprazole drug substance/drug

product LC determinations[21-23], Chemical structures and properties of Dexlansoprazole and

related Impurities shown in Table 1.

Table 1. Complete profile about the derivatives of Dexlansoprazole

S.No	Name	Chemical Formula	IUPAC Name	M. Wt	Structure
1	DEXP	$C_{16}H_{14}F_3N_3O_2S$	2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole	369.36	
2	DEXP RC-A	$C_{14}H_{12}ClN_3OS$	2-[(4-chloro-3-methylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole	305.78	
3	DEXP RC-B	$C_{16}H_{14}F_3N_3O_3S$	2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfonyl]-1H-benzimidazole	385.36	
4	DEXP RC-C	$C_{16}H_{14}F_3N_3OS$	2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]-1H-benzimidazole	353.36	
5	DEXP RC-D	$C_7H_6N_2O$	1H-benzo[d]imidazol-2-ol; 2-Benzimidazolol; 1H-benzimidazol-2-ol	134.14	
6	DEXP RC-E	$C_7H_6N_2S$	1,3-Dihydro-2H-benzimidazole-2-thione	150.20	
7	DEXP RC-F	$C_{14}H_{12}ClN_3OS$	2-[[[4-Chloro-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole	305.78	

II. MATERIAL AND METHODS

CHEMICAL REAGENTS

The ACS grade of Orthophosphoric acid was procured from Macron chemicals, USA. The

HPLC grade of Acetonitrile (J.T. beaker) with certified purity of 99.9% was purchased from Avantor performance materials, LLC, Radnor, PA, USA. The ACS grade of Hydrochloric Acid &

NaOH pellets was procured from VWR Chemicals, USA. The HPLC grade of Triethyl amine Supplied for Alfa Aesar, USA. The ACS grade of Hydrogen peroxide was purchased from Avantor performance materials, LLC, Radnor, PA, USA. High quality In-House purity water was used for the experiments (TOC<500ppb, pH about 7.0, Conductivity< 1.0 $\mu\text{s}/\text{cm}$, finally exposed to UV radiation and followed filtered through 0.2 μm filter). Dexlansoprazole 100% purity was procured from Aspire Life sciences Pvt Ltd. Mumbai, India.

INSTRUMENTATION AND SOFTWARE

UV-1800 Shimadzu Double beam with UV probe software UV-Visible spectrophotometer with 1cm matched quartz cells.

Waters HPLC system Alliance e2695 separation module with auto injector, temperature controller for sample storage and column was used for current analysis. The signal output was observed through Empower 3 Software Build 3471 SPs Installed: Feature Release 3 DB ID: 2639633283. The LC column is X-Terra RP₁₈ column (250 \times 4.6mm, 5 μm . manufactured by GL Sciences Inc. Analytical balance model CP225D (make: Sartorius), Top load balance model GP5202 (make: Sartorius) sonicator (make: LIFE CARE),

pH Meter (make: ORION 3STAR), Thermal oven(make: NEWTRONIC) were employed in this work.

DETERMINATION OF AMAX BY UV-SPECTROSCOPY

The suitable wavelength for the determination of Dexlansoprazole in diluent is identified by scanning over the range 200–400nm with a Shimadzu UV-160 (Shimadzu, Japan) double beam spectrophotometer.

PREPARATION OF SAMPLE SOLUTION BY UV-SPECTROSCOPY

A Sample Stock Solution of DEXP (50 $\mu\text{g mL}^{-1}$) was prepared by dissolving DEXP (10.0mg), in the Diluent (The Diluent was prepared by 0.1 N sodium hydroxide and Acetonitrile in the ratio of 60:40 v/v) to make 10 mL of solution (Stock Solution 1), Sample working solutions were prepared by quantitatively transferring 0.5 mL of Sample Stock Solution-1 separately into 10 mL volumetric flasks and made to volume with Diluent.

Adjust the baseline to zero using diluent as blank. Take the spectrum for Dexlansoprazole as shown in **Fig.1**.




Fig. 1: UV Spectrum of Dexlansoprazole

PREPARATION OF SYSTEM SUITABILITY SOLUTION

A System suitable Stock Solution of DEXP & SULF (240 $\mu\text{g mL}^{-1}$) was prepared by dissolving DEXP & SULF (30.0mg), in the Diluent (The Diluent was prepared by 0.1 N sodium hydroxide and Acetonitrile in the ratio of 60:40

v/v) to make 50 mL of solution (Stock Solution 1), Standard working solutions were prepared by quantitatively transferring 4.0 mL of System suitable Stock Solution-1 separately into 10 mL volumetric flasks and made to volume with Diluent. System suitability chromatograms are shown in **Fig. 2**.




Fig. 2: Chromatogram for System suitability solution

PREPARATION OF STANDARD SOLUTION

A Standard Stock Solution of DEXP (240 $\mu\text{g mL}^{-1}$) was prepared by dissolving DEXP (30.0mg), in the Diluent (The Diluent was prepared by 0.1 N sodium hydroxide and Acetonitrile in the ratio of 60:40 v/v) to make 50 mL of solution (Stock Solution 1), Standard working solutions

were prepared by quantitatively transferring 4.0 mL of Standard Stock Solution-1 separately into 10 mL volumetric flasks and made to volume with Diluent. Standard chromatograms are shown in Fig. 3. Results of the System suitability is summarized in Table 2.

Table 2. System suitability results

Parameters	Dexlansoprazole	Sulfone	Acceptance criteria
RT(min)	7.09	9.13	$\pm 10\%$
USP Tailing factor	1.12	1.09	NMT 2.0
USP Plate count	7036	7675	NLT 3000
USP Resolution	NA	5.30	NLT 3.0
% RSD	0.3	0.5	NMT 2.0




Fig. 3: Chromatogram for Standard

PREPARATION OF SAMPLE SOLUTION

An equivalent weight of 30 mg of Dexlansoprazole was transferred into a 50 mL volumetric flask. To this 30 mL of 0.1 N NaOH was added and sonicate for 15 min till the pellets dissolve completely. Then made up the volume with diluent and centrifuged.

From above solution 4 mL was taken in 10 mL volumetric flask and made up to the mark with diluent.

CHROMATOGRAPHIC CONDITIONS

The chromatographic partition was achieved using 10 mm dibasic potassium phosphate buffer was prepared and pH of the solution was adjusted to 7.20 with dilute Orthophosphoric acid: Acetonitrile: TEA in the ratio of 70:30:1 v/v/v. As the mobile phase at flow rate 1.2 mL min⁻¹. The LC column was used X-Terra RP₁₈column (250×4.6mm, 5µm). The injection volume was 10µL and detection of components was made at 285 nm.

III. RESULTS AND DISCUSSION

METHOD DEVELOPMENT AND OPTIMIZATION

The analytical method development was initiated based on the chemical structure and functional groups of Dexlansoprazole together with solubility. The component pKa of Dexlansoprazole (pKa 8.87). For initial HPLC method development experiment was started based on the structural polarity. Estimation of Dexlansoprazole different mobile phases, solvent–buffer ratios were tried to proposed final chromatographic conditions. The selection of TEA is used to improve the chromatographic retention control and peak shape improvement of the compound. The effects of this amine on the tailing Factor and Theoretical plate count of the compound. Dexlansoprazole is soluble in CH₃CN. The peak shapes, the symmetry of Dexlansoprazole were good with mobile phase buffer was selected (pH 7.2) 10 mm dibasic potassium phosphate buffer along with Acetonitrile: TEA in the ratio of 70:30:1 v/v/v. Using X-Terra RP₁₈column (250×4.6mm, 5µm at flow rate 1.2 mL min⁻¹. Selected Diluent was prepared by 0.1 N sodium hydroxide and Acetonitrile in the ratio of 60:40 v/v. The developed method was successfully useful to estimate the amount of Dexlansoprazole.

METHOD VALIDATION

Analytical method validation is essential to ensure that the analytical procedure employed for a specific test is appropriate for its intended. Subsequent to method development, analytical techniques must be validated before and for the duration of routine use. The parameters that were evaluated during contemporary method

development include specificity, linearity, range, accuracy, robustness, & precision.

The proposed method was validated based on International Conference on Harmonization (ICH) Q2 (R1) guidelines[24-26].

SPECIFICITY

An essential obligatory as ICH guideline for method validation is specificity or selectivity. In additional words, the specificity is the capability to evaluate the purity of the analyte in the being there of the co-eluting or co-migrating impurity. Neglecting peak purity authentication means, in quality control, an impurity concealed under a peak could fabricate the results. The theory of the photodiode array detector (PDA) compares the spectra involuntarily & report similarity factor for each peak in addition a three-dimensional image helps to verify selectivity without any superfluous workload, consequently, placebo interference was evaluated by using the PDA detector between 200 and 400 nm. The purity of active ingredients was unaffected by the presence of its impurities and thus stability-indicating power of the developed method.

FORCED DEGRADATION

The forced degradation studies were performed to demonstrate whether the analytical method was stability indicating and might unambiguously evaluate the analyte in the presence of impurities and degradation products[27-32]. The solutions of a drug product and placebo were exposed to acid hydrolysis (1N HCl), base hydrolysis (1N NaOH), oxidation (30% H₂O₂), thermal (Heat_105°C) to form degradation products. The liberated degradation products evaluated in terms of co-elution with close eluting with any components in the chromatography and initiate to be selective and unambiguous. The % total degradation (inference of major degradation impurities/products produced with respect to relative retention), mass balance and peak purity results of the stress condition is summarized in **Table 3**. Stressed samples chromatograms are shown in **Fig.4(4A-4D)**. The formula for % mass balance and % degradation is obtainable as follows.

$$\% \text{ Degradation} = \frac{\% \text{ Assay}_{\text{Ctrl SpL}} - \% \text{ Assay}_{\text{Deg SpL}}}{\% \text{ Assay}_{\text{Ctrl SpL}}} \times 100$$

$$\% \text{ Mass Balance} = \frac{\% \text{ Assay}_{\text{Deg SpL}} + \% \text{ Total impurities}_{\text{Deg SpL}}}{\% \text{ Assay}_{\text{Ctrl SpL}} + \% \text{ Total impurities}_{\text{Ctrl SpL}}} \times 100$$




Fig. 4A: Typical Chromatogram of Acid degradation




Fig. 4B: Typical Chromatogram of Base degradation




Fig. 4C: Typical Chromatogram of peroxide degradation




Fig. 4D: Typical Chromatogram of Thermal degradation

Table 3: Summary of forced degradation results

Stress Condition	% Assay of DEXP	% Total Impurities found	% Mass Balance	Dexlansoprazole	
				PA	PT
Control-Sample	99.0			0.127	0.304
1N HCl, refluxed at 80°C for 30min	88.3	10.2	98.6	0.188	0.353
1N NaOH, refluxed at 80°C for 30min	97.1	1.8	98.9	0.166	0.321
30% H ₂ O ₂ , refluxed at 80°C for 30min	90.0	8.5	98.5	0.541	0.625
Thermal 105° C for 1 hr	93.3	6.2	99.6	0.222	0.315

PA- Purity Angle, PT- Purity Threshold

PRECISION

In method precision, a homogenous test of a single batch was analyzed six times. This informs you if a method consistently produces consistent results for a single batch. Calculate the average results (X), standard deviation (SD), and the percent relative standard deviation (%RSD), and the results are presented in **Table 4**. The method was found to be precise since the RSD values method precision was below 1.0.

LIMIT OF QUANTIFICATION & LIMIT OF DETECTION

The LOQ and LOD are determined based on signal-to-noise ratios at analytical responses of 10 and 3 times the and the results are presented background noise, respectively in **Table 4**.

LOD (mg/L) = $3 \times \frac{\text{Noise}}{\text{Signal}}$ x Lowest concentration of the linearity samples

LOD (mg/L) = $10 \times \frac{\text{Noise}}{\text{Signal}}$ x Lowest concentration of the linearity samples

LINEARITY

It refers to an assay's ability to yield test results that are proportional to the concentration of analyte in the sample. The range of the analytical assay will be calculated by evaluating this parameter.

Linearity of the method was determined by constructing calibration curves. Standard solutions of Dexlansoprazole of different concentrations levels (50%, 75%, 100%, 125%, and 150%) prepared by serial dilution of standard stock solution) were used for this purpose. The results are presented in **Table 4**. Linearity Curve for DEXP: **Fig. 5**.




Fig. 5: Linearity plot of Dexlansoprazole

ACCURACY

The accuracy of an experimental data is the degree to which the method's test results are similar to the true value. Accuracy may often be expressed as percent of recovery by the test of known added amounts of analyte. Accuracy was measurement of exactness of the analytical method.

In this HPLC method, the recovery of the samples was verified with three concentration levels (50%, 100% & 150%). The recovery was performed by API+Placebo and injected into the HPLC (triplicate) and the results are presented in **Table 4**.

Table 4. Method validation parameters

Parameters	Dexlansoprazole
Linearity (50-150%)	
Range ($\mu\text{g mL}^{-1}$)	50-150
Slope	18247.456
Intercept	32894.800
Correlation Coefficient	0.9997
STYX SD	17062.002
LOD ($\mu\text{g mL}^{-1}$)	0.14
LOQ ($\mu\text{g mL}^{-1}$)	0.028
Accuracy^(a)(% of Recovery)	
50% Mean \pm SD	99.5 \pm 0.91
100% Mean \pm SD	100.1 \pm 0.66
150% Mean \pm SD	100.8 \pm 1.22
Precision^(b)(%RSD)	
Repeatability	0.5
Intermediate precision	0.8
^{a)} Average of three determinations of each concentration level ^{b)} %RSD of six determinations of each component Linearity and other validation parameters results obtained by the proposed HPLC.	

ROBUSTNESS

Small deliberate variations in the optimised system parameters were done to test the robustness of the established RP-HPLC method. The effect of change in flow rate, temperature, pH and ratio of Acetonitrile composition in mobile phase on the retention time and tailing factor were studied. The method was found to be unaffected by small changes ± 0.2 ml/min change in flow rate, $\pm 5^\circ\text{C}$ change in temperature, $\pm 10\%$ of Organic Phase (Acetonitrile) and Mobile phase pH ($\pm 0.2\%$), the tailing factor and the plate count for the Dexlansoprazole peak area for five replicate injections of standard were found to be within the acceptable limit of not more than 2.0%, illustrating the robustness of the method.

IV. CONCLUSION

Rapid, simple and stability-indicating HPLC method has been developed effectively for Dexlansoprazole delayed-release capsules. The developed and validated HPLC method can accurately quantitate the Dexlansoprazole in finished product. This method provides discriminating quantification of Dexlansoprazole component lacking interference of blank, placebo, impurities and/or degradation products in that way affirming the stability-indicating character of the method. In addition, this method was environmental, biodegradable and less hazardous. This is for the reason that it spends less quantity of toxic organic solvent and therefore produces small amount of toxic waste. The HPLC method was successfully used for the analysis of Dexlansoprazole delayed-release capsules in quality control lab for stability analysis.

ACKNOWLEDGEMENTS

There was no funding received from any agency. Sincere thanks to the Aurex laboratories Pvt. Ltd. management for giving the approval for the publication of the article.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- [1]. Sun LN, Cao Y, Li YQ, Fang YQ, Zhang HW, Wang MF, et al. (2017) Impact of Gastric H⁺/K⁺-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects. *Front Pharmacol* 2017;8:670. doi: 10.3389/fphar.2017.00670
- [2]. Shin J M, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: Structure, function, and inhibition. *Pflugers Arch Eur J Physiol* 2009;457: 609–622.
- [3]. Patel MM, Bhuvra SD, Patel HD, Mori KN. An overview of the recent developments in analytical methodologies for determination of proton pump inhibitors in bulk drugs, pharmaceuticals and biological matrices. *Eurasian J Anal Chem* 2014;9: 49–57.
- [4]. Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - A new-generation proton pump inhibitor. *PrzGastroenterol* 2015;10:191–196.
- [5]. Chen L, Chen Y, Li B. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: A network meta-analysis. *Sci Rep* 2016;6: 1–9.
- [6]. Shin, Sachs. *Pharmacology of proton pump inhibitors (PPIs)*. 2016;
- [7]. Frye JW, Peura DA. Managing gastroesophageal reflux disease - Comparative efficacy and outcomes of dexlansoprazole MR. *Ther Clin Risk Manag* 2015;11: 1649–1656.
- [8]. Rimmani HH, Rustom LBO, Rahal MA, Shayto RH, Chaar H, Sharara AI. Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan. *Dig Dis* 2019;37(3):188-193. doi: 10.1159/000496091.
- [9]. Zhang J, Qi J. Comparison of Bioavailability: Two Dexlansoprazole Formulations in Beagle Dogs after a Single Dose Administration. *J Bioequiv Availab* 2013;08:140–144.
- [10]. Geetharam, Yanamadala, Praveen srikumar, Rushyendra G, Ramamohanupta S. Stability indicating validated novel RP-HPLC method for the estimation of Dexlansoprazole in bulk and extended release capsules. *Indo Am J Pharm Res* 2013;3: 8454–8466.
- [11]. Abel C, Desilets AR, Willett K. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. *Ann Pharmacother* 2010;44: 871–877.
- [12]. Wu JCY, Sheu BS, Wu MS, Lee YC, Choi MG. Phase 4 study in patients from Asia with gastroesophageal reflux disease treated with dexlansoprazole. *J Neurogastroenterol Motil* 2020;26: 85–95.
- [13]. Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A, Hsu PI. A Pilot Randomized Controlled

- Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. *Medicine (Baltimore)* 2016;95(11):e2698. doi:10.1097/MD.0000000000002698
- [14]. Attumi TA, Graham DY. High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy for Helicobacter pylori Infections. *Helicobacter* 2014;19:319–322.
- [15]. Kuo CJ, Chen CW, Le PH, Hsu JT, Lin CY, Cheng HT, et al. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections. *TherapAdvGastroenterol* 2019;12:1756284819870960. doi:10.1177/1756284819870960.
- [16]. Takeda Pharmaceuticals America, I. Reference ID: 3193076 Reference ID: 3193076. *MedicatGuid* 2012;1–15.
- [17]. Aslam N, Wright R. Dexlansoprazole MR. *Expert OpinPharmacother* 2009;10:2329–2336.
- [18]. Monopril. Product Monograph Monopril * Product Monograph 2012;1–71.
- [19]. Gaba M, Mohan C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: Recent advances and future directions. *Medicinal Chemistry Research* 2016;25.
- [20]. Harron DWG. Technical Requirements for Registration of Pharmaceuticals for Human Use: The ICH Process. *Textb Pharm Med* 1994; 447–460.
- [21]. Sriharsha J, Srinivasa Murthy M, Bharat Kumar D, Sravan K, Shivakumar P, Shirisha A, et al. Method Development and Validation for Simultaneous Estimation of Dexlansoprazole and Meloxicam by Rp-Hplc. *Pharm Anal Acta* 2015;6:370. doi:10.4172/21532435.1000370
- [22]. Narasimha LKR, Dongala T, Ettaboina SK. Quality by Design with Design of Experiments Approach for development of Stability Indicating LC Method for Enzalutamide and its Impurities in Soft gel Dosage Formulation. doi:10.1002/bmc.5062
- [23]. Nakkala K, Godiyal S, Laddha KS. Isolation of starch from Curcuma longa L. and its characterization. *Int J Pharm Sci Res* 2020;11(11):5712-17. doi:10.13040/IJPSR.0975-8232.11(11).5712-17.
- [24]. Godiyal S, Nakkala K, Laddha KS. Separation of starch from Zingiberofficinale (ginger) and study it's characterization. *Int J Pharm Sci Res* 2021;12(1):459-64. doi:10.13040/IJPSR.0975-8232.12(1).459-64.
- [25]. Hotha KK, Bharathi DV, Jagadeesh B, Ravindranath LK, Jaya Veera KN, Venkateswarulu V. Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study. *Biomed Chromatogr* 2012; 26:192-198.
- [26]. Macha B, Nakkala K, Garige AK, Akkinapally RR, Garlapati A. SYNTHESIS AND EVALUTION OF NEW TACRINE DERIVATIVES AS ANTI-ALZHEIMER'S AGENTS. *International Journal of Pharmacy and Biological Sciences* 2018;8:590-597.
- [27]. Katakam LNR, Dongala T, Ettaboina SK. Novel stability indicating UHPLC method development and validation for simultaneous quantification of hydrocortisone acetate, pramoxine hydrochloride, potassium sorbate and sorbic acid in topical cream formulation. *Talanta Open* 2020; 1, 100004. doi:10.1016/j.talo.2020.100004
- [28]. Katakam LNR, Ettaboina SK, Mariseti VM. Development and Validation of LC-MS method for the determination of Heptaethylene glycol monomethyl ether in Benzonatate bulk drugs. *Biomedical Chromatography* 2021;https://doi.org/10.1002/bmc.5096
- [29]. Dongala T, Katari NK, Ettaboina SK, Krishnan A, Tambuwala MM and Dua K. In vitro Dissolution Profile at Different Biological pH Conditions of Hydroxychloroquine Sulfate Tablets Is Available for the Treatment of COVID-19. *Front. Mol. Biosci* 2021; 7:613393. doi:10.3389/fmolb.2020.613393
- [30]. Katakam LNR, Ettaboina SK, Dongala T. Determination of Oligomer Content in Benzonatate Drug Substance by HPLC. *European Journal of Scientific Exploration*2020; 3(2):30–39. https://syniutajournals.com/index.php/EJSE/article/view/183
- [31]. Katakam LNR, Dongala T. Quality by design with design of experiments approach for the development of a stability-indicating LC method for benzonatate and its impurities in liquid oral dosage form. *SEPARATION SCIENCE PLUS* 2020;. doi:10.1002/sscp.202000023



- [32]. Katakam LNR, Dongala T. A Novel RP-HPLC Refractive Index Detector Method Development and Validation for Determination of Trace Level Alcohols (Un-Sulfated) in Sodium Lauryl Sulfate Raw Material. *Biomedical Chromatography* 2020; doi:10.1002/bmc.4827